Get started
Author

Hadija Hamis Semvua

Observed names: H Semvua, H. H. Semvua, Hadija H Semvua, Hadija H. Semvua, Hadija Hamisi Semvua, Hadija S Semvua, Hadija Semvua, Semvua H. H., Semvua Hadija, Semvua, H, Semvua, H.H., Semvua, Hadija, Semvua, Hadija H.
Observed institutions: Radboud University Nijmegen, Radboud University Medical Center, Tumaini University, Kilimanjaro Christian Medical Centre, KCMC University, Kilimanjaro Clinical Research Institute
ORCID: 0000-0002-1352-5899
Observed ORCID: 0000-0002-1352-5899
OpenAlex ID: A5017234432
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial
2016 · Martin J Boeree, Norbert Heinrich, et al. · The Lancet Infectious Diseases · 378
PDF
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients
2015 · Norbert Heinrich, Rodney Dawson, et al. · Journal of Antimicrobial Chemotherapy · 93
PDF
Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis
2017 · R. E. Aarnoutse, G. S. Kibiki, et al. · Antimicrobial Agents and Chemotherapy · 92
PDF
Pharmacokinetics of First-Line Tuberculosis Drugs in Tanzanian Patients
2013 · Alma Tostmann, Charles M. Mtabho, et al. · Antimicrobial Agents and Chemotherapy · 65
PDF
Phenotypic Changes on Mycobacterium Tuberculosis-Specific CD4 T Cells as Surrogate Markers for Tuberculosis Treatment Efficacy
2018 · Mohamed I. M. Ahmed, Nyanda E. Ntinginya, et al. · Frontiers in Immunology · 56
PDF
Pharmacological Interactions Between Rifampicin and Antiretroviral Drugs
2014 · Hadija H. Semvua, Gibson S. Kibiki, et al. · Therapeutic Drug Monitoring · 52
Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania
2017 · Seleman Khamis Semvua, Catherine Orrell, et al. · PLoS ONE · 45
PDF
Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting
2015 · I. Marion de Sumari-de Boer, Jossy van den Boogaard, et al. · AIDS and Behavior · 40
Prevalence and factors associated with tuberculosis among the mining communities in Mererani, Tanzania
2023 · Alexander W. Mbuya, Innocent B. Mboya, et al. · PLoS ONE · 33
Effect of diabetes mellitus on TB drug concentrations in Tanzanian patients
2019 · Charles M Mtabho, Hadija H Semvua, et al. · Journal of Antimicrobial Chemotherapy · 33
PDF
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30
PDF
Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial
2019 · Marion Sumari-de Boer, Francis M. Pima, et al. · Trials · 27
PDF
Efavirenz, Tenofovir and Emtricitabine Combined with First-Line Tuberculosis Treatment in Tuberculosis–Hiv-Coinfected Tanzanian Patients: A Pharmacokinetic and Safety Study
2012 · Hadija H Semvua, Charles M Mtabho, et al. · Antiviral Therapy · 24
Protein binding of rifampicin is not saturated when using high-dose rifampicin
2018 · Carlijn H C Litjens, Rob E Aarnoutse, et al. · Journal of Antimicrobial Chemotherapy · 21
PDF
Concentrations of respirable crystalline silica and radon among tanzanite mining communities in Mererani, Tanzania
2023 · Alexander W Mbuya, Innocent B Mboya, et al. · Annals of Work Exposures and Health · 15
PDF
The evolution of haematological and biochemical indices in HIV patients during a six-month treatment period.
2012 · J Mgogwe, H Semvua, et al. · PubMed · 15
PDF
Sale of fluoroquinolones in northern Tanzania: a potential threat for fluoroquinolone use in tuberculosis treatment
2009 · J. van den Boogaard, H. H. Semvua, et al. · Journal of Antimicrobial Chemotherapy · 15
Prevalence and determinants of evidence of silicosis and impaired lung function among small scale tanzanite miners and the peri-mining community in northern Tanzania
2024 · Alexander W. Mbuya, Innocent B. Mboya, et al. · PLOS Global Public Health · 14
PDF
Antituberculosis drug‐induced hepatotoxicity is uncommon in Tanzanian hospitalized pulmonary TB patients
2010 · Alma Tostmann, Jossy Van Den Boogaard, et al. · Tropical Medicine & International Health · 14
Low rate of fluoroquinolone resistance in Mycobacterium tuberculosis isolates from northern Tanzania
2011 · J. van den Boogaard, H. H. Semvua, et al. · Journal of Antimicrobial Chemotherapy · 13
PDF
A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
2021 · Stijn W. van Beek, Rob ter Heine, et al. · Clinical Pharmacokinetics · 12
PDF
Clinical outcomes of new algorithm for diagnosis and treatment of Tuberculosis sepsis in HIV patients
2019 · Kenneth Byashalira, Peter Mbelele, et al. · International Journal of Mycobacteriology · 12
Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials
2023 · Emmanuel Musisi, Adam Wyness, et al. · The Lancet Microbe · 11
PDF
Implementation of evidence-based multiple focus integrated intensified TB screening to end TB (EXIT-TB) package in East Africa: a qualitative study
2023 · Kahabi Isangula, Doreen Philbert, et al. · BMC Infectious Diseases · 9
PDF
Demographic and clinical determinants of multi drug resistant tuberculosis among HIV infected patients in Tanzania
2020 · Mgogwe John, Semvua Hadija, et al. · International Journal of Medicine and Medical Sciences · 9
PDF
Works count: 74
Citation count: 1,204
H-index: 15
I10-index: 23
Year
Topic
Type